Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Capricor Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$25.8

+1.16 (+4.63%)

C 54Pipeline Score Overvalued Pharma · Commercial
Market Cap
1.67 B
EPS
-2.31
P/E Ratio
-
Value Trade
18.26 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • R&D Expenses

    27.38 M

  • Operating CF

    -29.25 M

  • Total Assets

    326.28 M

  • Total Liabilities

    47.58 M

  • Equity

    278.70 M

  • D/E Ratio

    12,345

-0.82 %
Week
-19.29 %
1 Month
0.59 %
3 Month
412.79 %
6 Month
644.07 %
5 Year
-96.39 %
All Time
Cash Data
Healthy

  • Cash Position

    278.61 M

  • Monthly Burn

    9.75 M

  • Runway

    27.7 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 13, 2026
Overview
Volume
773.70 K
52 Week Range
4.30 - 40.37
% held by Insiders
9.68 %
% held by Institutions
59.04 %
Enterprise Value
1.41 B
Total Shares
57.83 M
Short %
26.69 %
Float Shares
41.47 M
Company Description
HQ: 10865 ROAD TO THE CURE, SAN DI...
Employees:231
https://www.capricor.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA Date example
Deramiocel (CAP-1002) Duchenne muscular dystrophy (DMD)
PDUFA
—
Cell Therapies
Musculoskeletal System
Deramiocel (CAP-1002) Duchenne muscular dystrophy (DMD)
PDUFA
—
Cell Therapies
Musculoskeletal System
Deramiocel (CAP-1002) Duchenne muscular dystrophy (DMD)
PDUFA
—
Cell Therapies
Musculoskeletal System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C54
Pipeline Score
$677M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.4x
rNPV / MCap
Top 80%
Micro Cap
(rank 182 of 905)
Percentile Rank
Capricor Therapeutics, Inc. carries a moderate pipeline score (54/100), with $1.7B risk-adjusted pipeline value, led by Deramiocel in Muscular Dystrophies (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Deramiocel
Monoclonal antibody		Muscular DystrophiesPhase 3NCT0512675890% $875M ACTIVE NOT_RECRUITING 106 STALLED B (78) Dec 1, 2026LOW_RISKLOW
Jun 5, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Deramiocel
Duchenne Muscular Dystrophy
Phase 2
2025-06-23
Deramiocel
Duchenne Muscular Dystrophy
Phase 2
2025-06-23
Deramiocel
Duchenne Muscular Dystrophy
Phase 2
2025-06-23
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in CAPR
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CAPR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CAPR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CAPR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
CAPR Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
CAPR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-17 0.00 0 - - - - - -
2026-07-17 0.00 0 - - - - - -
2026-07-17 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Capricor Therapeutics, Inc. (CAPR) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How CAPR ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Rare Neurological Disorders #8 of 46 PHASE 3 Deramiocel
IONS BIIB SRPT
$139.4B 0.93 CONTENDER
Rare Genetic Disorders #11 of 61 PHASE 3 Deramiocel
BMRN ASND NVS
—0.95 CONTENDER